heparegenix-logo.png
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
March 14, 2024 11:35 ET | HepaRegeniX GmbH
Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniXHRX-215 proved to be safe and...
Allyx.jpg
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
March 11, 2024 08:05 ET | Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
BioNTech to Present
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024 07:45 ET | BioNTech SE
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association...
BioNTech präsentiert
BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten
March 11, 2024 07:45 ET | BioNTech SE
MAINZ, Deutschland, 11. März 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom...
Nurix.png
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
March 11, 2024 07:00 ET | Nurix Therapeutics, Inc.
Nurix's Phase 1a/1b study of NX-2127 in adults with r/r B-cell malignancies to enroll new patients after partial clinical hold lifted
23andMe_Logo_grey.png
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:30 ET | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...
myriad_S_stacked.png
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024 09:15 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National...
MNPR Triangle 2.JPG
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
February 27, 2024 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024 08:00 ET | Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
intrommune_icon_500x500.png
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
February 22, 2024 09:34 ET | Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects